ALX Oncology (NASDAQ:ALXO) executives said the company is focused on advancing two clinical-stage oncology programs, with upcoming data readouts expected to shape potential later-stage development plans for its lead CD47 program, evorpacept, and its EGFR-targeted antibody-drug conjugate, ALX2004.
Speaking at the Jefferies 2026 Global Healthcare Conference, Jason Lettmann, chief executive officer of ALX Oncology, said the company is coming off “a strong ASCO” and has gained momentum over the past several months. He said ALX has been working on CD47 for close to a decade and believes recent clinical findings support the company’s original approach to the target.
